High Flow Therapy (HFT) to Treat Respiratory Insufficiency in Chronic Obstructive Pulmonary Disease (COPD)

Withdrawn before enrolling · Not applicable

Conditions studied: Pulmonary Disease, Chronic Obstructive, Respiratory Insufficiency

In brief

The aim of this study is to see if the Vapotherm High Flow Therapy (HFT) device is effective to provide breathing support to patients with Chronic Obstructive Pulmonary Disease or COPD. The investigators believe that patients using HFT will not require as much use of therapies that provide pressure through a face mask, and are already recognized by FDA as support therapies for respiratory insufficiency.

Key facts

Study ID

NCT00990119

Run by

Vapotherm, Inc.

People needed

0

Starts

2009-09-01

Expected to finish

2014-04-01

Last updated by the study team

2020-09-16

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Present to the Emergency Department with a history of COPD and with symptoms consistent with a diagnosis of respiratory insufficiency and exacerbation of COPD
• Must be hemodynamically stable as judged by treating clinician in the ED
• Primary complaint is shortness of breath, and presumed diagnosis is exacerbation of COPD

You may not qualify if…

• Fever
• Radiographic evidence of pneumonia
• Glasgow Coma score < 14 or unable to correctly answer at least one study-specific question

Where it is running

• Temple University Hospital — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.